thromboxane

Thromboxane A2, as an unstable intermediate between the prostaglandin endoperoxides and thromboxane B2, is a potent inducer of platelet aggregation and causes vasoconstriction.

15(R)-Pinane thromboxane A2 is the (R)-epimer of pinane thromboxane A2 . 15(R)-PTA2 does not inhibit collagen-induced platelet aggregation (IC50s = 120-130 μM). It does not affect gastric tone in isolated rat gastric fundus when used at concentrations of 0.5 or 1.5 μg/ml and is less effective than PTA2 at inhibiting prostaglandin-induced contraction of isolated rat stomach muscle.

Thromboxane B2 (a prostaglandin derivative released during anaphylaxis) induces platelet aggregation and arterial contraction.

NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)

RS-601 is a potent dual leukotriene D4/thromboxane A2 inhibitor that inhibits antigen-induced airway hyperresponsiveness (AHR) and shows asthmatic effects in a guinea pig model of asthma.

AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.

Dazmegrel HCl is a platelet thromboxane inhibitor used in the study of myocardial infarction and arrhythmias.

Pirodomast is a thromboxane A (TXA2) synthase inhibitor. Pirodomast inhibits leukotriene (LT) D4, C4, E4 formation and thromboxane B2 (TXB2) activity, but is weakly or ineffectively antagonistic to guinea pig bronchospasm induced by histamine, methacholine, serotonin, LTC4, or platelet-activating factor. Pirodomast is a potential antiallergic compound. Pirodomast had only weak relaxant activity on guinea pig trachea in vitro. Pirodomast is a potential antiallergic compound that inhibits the protein hydrolyzing activity of trypsin in vitro, prevents antigen-induced immediate and late asthmatic responses in allergic sheep in vivo, and inhibits antigen-induced airway hyperresponsiveness to histamine and carbachol in allergic sheep.

Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

Ozagrel hydrochloride (OKY-046 HCl) is a selective thromboxane A(2) synthetase inhibitor used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

p-Hydroxycinnamic acid (NSC-59260) can inhibit platelet activity, with IC50s of 371 μM, 126 μM for thromboxane B2 production and lipopolysaccharide-induced prostaglandin E2 generation, respectively.

NP-313 (NSC-4264) is a potent antithrombotic agent that inhibits platelet aggregation and activation by inhibiting thromboxane A 2 synthesis and selectively inhibiting SOCC-mediated Ca2+ efflux.

9-Oxononanoic Acid is an oxidized fatty acid, formed by the autoxidation of linoleic acid, which enhances phospholipase A2 (PLA2) activity and increases the production of thromboxane B2 in isolated human plasma.9-Oxononanoic Acid reduces hepatic neofatty acid synthesis and enhances the activity of rat hepatic carnitine palmitoyltransferase, a marker of β-oxidation. Activity.

Dazoxiben (UK-37248) is a potent inhibitor of thromboxane (TX) synthase

Mulberrofuran Q is an active compound that inhibits the formation of 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and thromboxane B2 (cyclooxygenase product) , which protects neuronal cells from hypoxia-glycorrhoea-deficiency (OGD)-induced oxidative stress.

Thromboxane B1 (TXB1), a member of the Thromboxane B (TXB) family, is a lipid belonging to the eicosanoid family, recognized for its function in blood clot formation (thrombosis) [1].

Thromboxane B2 (Standard) is a reference standard for research and analysis in studies involving Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces platelet aggregation and arterial contraction.

Thromboxane B2 ethanolamide (TXB2-EA) is a metabolite of thromboxane A2 ethanolamide. It is produced through the hydrolysis of thromboxane A2 ethanolamide.

Thromboxane B2 (TXB2) is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2. In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2. However in human urine, only trace amounts of 2,3-dinor TXB1 have been identified. In rats, 2,3-dinor TXB1 is excreted at a much higher rate than 2,3-dinor TXB2 (19.2 ± 4.9 ng/24 hr and 1.6 ± 0.3 ng/24 hr, respectively). Therefore, urinary 2,3-dinor TXB1 is a suitable marker of thromboxane biosynthesis in rats.

Carbocyclic Thromboxane A2 can be used in related research in the field of life sciences. Its product number is T36548 and CAS number is 74034-56-3.

Thromboxane B3 (TXB3), the stable hydrolysis product of TXA3, is synthesized from eicosapentaenoic acid (EPA) through the action of COX and thromboxane synthase enzymes. This compound is biosynthesized in several tissues, including seminal vesicles, lungs, polymorphonuclear leukocytes (PMNL), and ocular tissues.

11-Dehydro Thromboxane B3 (11-dehydro TXB3) serves as a urinary metabolite of TXA3 in humans following an increased dietary intake of EPA.